Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$354.3MMiss by $92.2M
EPS$1.72Beat by $0.09
Revenue estimate$446.5M
EPS estimate$1.63

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$402.3M
EPS estimate$1.82

Financials

Q3 2025

Income statement

See full
Revenue$354.3M+22.1%
Gross profit$299.0M+24.3%
Operating income$217.9M+33.5%
Net income$175.2M+27.9%
EPS (diluted)$1.43+36.2%

Balance sheet

See full
Cash & equivalents$419.7M+172%
Total debt$1.5B+0.3%
Total equity$503.9M+11.3%
Total assets$2.2B+4.9%

Cash flow

See full
Operating cash flow$178.6M+54.8%
CapEx$3.0M+99.7%
Free cash flow$175.6M+54.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$8.58B+17.9%
Enterprise value$9.7B+12.0%
P/E14.4×-4.1×
P/S6.9×-0.8×

Profitability

See full
Gross margin84.5%+2.5pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+7.0pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity3.1×-0.3×
Current ratio1.6×-8.8×

Segments

By product

See full
Royalties$236.0M+52.2%
Proprietary product sales$52.2M+30.9%
Bulk rHuPH20 sales$32.5M+3.2%
Sales-based milestones$20.0M—
Device partnered product sales$9.5M-37.7%

By geography

See full
All other foreign$8.3M+250%

Versus estimates

Revenue

Q1 2026$376.7MBeat by $18.1MQ4 2025$451.8MBeat by $16.1M
Q3 2025$354.3MMiss by $92.2M
Q2 2025$325.7MMiss by $5.1MQ1 2025$264.9MMiss by $16.1MQ4 2024$298.0MBeat by $12.3M

Diluted EPS

Q1 2026$1.60Beat by $0.06Q4 2025-$0.24Miss by $2.39
Q3 2025$1.72Beat by $0.09
Q2 2025$1.54Beat by $0.31Q1 2025$1.11Beat by $0.16Q4 2024$1.26Beat by $0.09

Ask the moment Halozyme Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Halozyme Therapeutics report Q3 2025 earnings?
Halozyme Therapeutics (HALO) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Halozyme Therapeutics's Q3 2025 revenue and EPS?
Halozyme Therapeutics reported revenue of $354.3M and eps of $1.72 for Q3 2025.
Did Halozyme Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $446.5M by $92.2M. EPS beat the consensus estimate of $1.63 by $0.09.
How did Halozyme Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.1% from $290.1M a year earlier and eps grew 35.4% from $1.27.
Where can I find Halozyme Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001159036-25-000044) and the 10-Q periodic report (0001159036-25-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.